Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jul 16, 2026
Genprex, Inc. (GNPX)
A forensic read on Genprex, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-57.4
Altman Z-score
Clean
Earnings quality
2
Forensic signals
Genprex, Inc. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is -57.4, placing it in the Distress zone. 2 forensic signals were flagged in its latest SEC filings, led by accruals ratio.
What the filings flag
+150.5%Accruals ratio.Net operating assets grew +150.5% relative to their average in FY2025 — the accrual component of earnings. Accruals are building sharply — a large slice of profit sits in operating assets, not cash; Richardson/Sloan link high accruals to weaker future returns as they reverse. The cash-flow cross-check is more mixed: reported earnings ran behind operating cash by 1228% of net operating assets, diverging from the balance-sheet accrual read.
-7984%Return on invested capital.Return on invested capital is -7984% in the latest fiscal year and slipping from -1426% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
Key fundamentals
Free Cash Flow$-14.3M
Return on Equity-203.8%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Genprex, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about GNPX's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown